NASDAQ: BCDABiocardia Inc Stock
$0.37-0.01 (-2.63%)
Updated Apr 25, 2024
BCDA Price
$0.37
Fair Value Price
-$0.25
Market Cap
$9.84M
52 Week Low
$0.32
52 Week High
$2.92
P/E
-0.67x
P/B
-6.14x
P/S
29.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$477.00k
Earnings
-$11.57M
Gross Margin
100%
Operating Margin
-2,425.79%
Profit Margin
-2,425.8%
Debt to Equity
-2.86
Operating Cash Flow
-$10M
Beta
0.53
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BCDA Overview
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BCDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCDA ($0.37) is overvalued by 245.07% relative to our estimate of its Fair Value price of -$0.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCDA ($0.37) is not significantly undervalued (245.07%) relative to our estimate of its Fair Value price of -$0.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCDA due diligence checks available for Premium users.
Be the first to know about important BCDA news, forecast changes, insider trades & much more!
BCDA News
Valuation
BCDA fair value
Fair Value of BCDA stock based on Discounted Cash Flow (DCF)
Price
$0.37
Fair Value
-$0.25
Undervalued by
245.86%
BCDA ($0.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCDA ($0.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCDA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.67x
Industry
15.41x
Market
40.97x
BCDA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.14x
Industry
5.8x
BCDA's financial health
Profit margin
Revenue
$13.0k
Net Income
-$2.1M
Profit Margin
-15,938.5%
BCDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BCDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.0M
Liabilities
$4.6M
Debt to equity
-2.86
BCDA's short-term liabilities ($3.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCDA's short-term assets ($1.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$0.0
Financing
$1.1M
BCDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCDA vs Biotech Stocks
Biocardia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.